[1] |
XIA Hui, ZHENG Yang, SONG Yuan-yuan.
Interpretation of the Optimized broth microdilution plate methodology for drug susceptibility testing of Mycobacterium tuberculosis complex issued by World Health Organization
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 641-645.
|
[2] |
LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu.
A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653.
|
[3] |
YU Chun-hong, LIU Xing, SHEN Ling-jun, LI Hai-wen, LI Xie, WU Rong-shuang, LI Xian-rui, FAN Hao.
Meta analysis of efficacy and safety of the treatment containing bedaquiline for multidrug-resistant pulmonary tuberculosis
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 660-668.
|
[4] |
DAI Xiao-wei, WANG Nen-han, CHEN Shuang-shuang, YANG Xin-yu, TIAN Li-li, CHEN Hong, ZHANG Hong-tai, LI Chuan-you.
Assessing next-generation sequencing for Mycobacterium tuberculosis diagnosis in clinical sputum samples
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 669-679.
|
[5] |
RAO Hai-tao, DONG Wei-jie, QIN Shi-bing.
The clinical features of 653 cases of thoracic spinal tuberculosis
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 675-680.
|
[6] |
KANG Wan-li, LI Tian-jing, WANG Sai-sai, LI Chang-hua, ZHAO Qiu-yue, ZHENG Su-hua, LIU Yang.
Study on the trend and prediction of reported incidence of national active pulmonary tuberculosis in China
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 681-684.
|
[7] |
CHEN Yan-mei, WEN Wen-pei, WU Hui-zhong, XU Liu-yue, PENG Ke-hao, YU Mei-ling.
Analysis of monitoring results of tuberculosis drug-resistance in Guangdong Province from 2016 to 2020
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 685-689.
|
[8] |
ZHONG Qian-hong, MA Xiao-hui, ZHONG Yong-hui, ZHAO Zhi-meng, ZHANG Xi-lin, XU Bang, LUO Jie-ying, ZHONG Li-ping, DAI Lei.
Analysis of recurrence rate of pulmonary tuberculosis patients in Foshan and the influencing factors from 2014 to 2018
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 690-697.
|
[9] |
GAO Li, PANG Xue-wen, ZHANG Guo-qin, LI Jing-xin, ZHANG Fan.
Analysis of risk factors for recurrence within 2 years after successful treatment of newly treated active pulmonary tuberculosis in Tianjin
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 698-703.
|
[10] |
XUE Xiao, ZHANG Dong-yan, AI Ping, DENG Ling, CHEN Wei, HU Yuan-lian, JIA Xue-jiao, YANG Guo-liang, XIN Zhen-jiang, CHANG Li-jie.
Analysis of the usage of electronic pillbox and WeChat App in pulmonary tuberculosis patients
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 704-710.
|
[11] |
NIE Wen-juan, ZHOU Wen-qiang, CHU Nai-hui.
Research progress on pharmacokinetics and drug interaction of bedaquiline
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 716-719.
|
[12] |
JIA Hong-yan, DONG Jing, ZHANG Zong-de, PAN Li-ping.
Progress and clinical application of immunological detection technology for Mycobacterium tuberculosis infection
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 720-726.
|
[13] |
YANG Chi, WANG Zhen-wei, SHA Wei.
Advances in research on treatments of multidrug-resistant tuberculosis with Chinese traditional medicine
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 727-731.
|
[14] |
TIAN Na, CHU Hong-qian, SUN Zhao-gang.
Recent progress of Nano-drug delivery system for tuberculosis treatment
[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 732-737.
|
[15] |
AN Hui-ru, WU Xue-qiong.
Interpretation of immunoadjuvant therapy in Expert consensus on immune function assessment and immunotherapy in patients with active tuberculosis (2021 Edition)
[J]. Chinese Journal of Antituberculosis, 2022, 44(6): 539-543.
|